AIM: To examine the effect of troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma) ligand, on the proliferation and apoptosis of human liver cancer cells. METHODS: Liver cancer cell line HepG2 was cultured and treated with troglitazone. Cell proliferation was detected by 3-(4-,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay; apoptosis was detected by flow cytometry and terminal deoxynucleotidyl transferase-mediated nick end labeling of DNA fragmentation sites (TUNEL) assay; and apoptosis-related protein was detected by immunocytochemistry and Western blotting. RESULTS: Troglitazone inhibited growth and induced apoptosis of HepG2 cells in a dose-dependent manner, and induced activation of caspase-3 expression. Troglitazone not only drove apoptosis-inhibiting factor survivin to translocate incompletely from the nucleus to the cytoplasm, but also inhibited expression of survivin, while it did not affect expression of apoptosis-promoting factor Bax. CONCLUSION: PPAR gamma ligands inhibit growth and induce apoptosis of liver cancer cells, and may have applications for the prevention and treatment of liver cancer.
AIM: To examine the effect of troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma) ligand, on the proliferation and apoptosis of humanliver cancer cells. METHODS:Liver cancer cell line HepG2 was cultured and treated with troglitazone. Cell proliferation was detected by 3-(4-,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay; apoptosis was detected by flow cytometry and terminal deoxynucleotidyl transferase-mediated nick end labeling of DNA fragmentation sites (TUNEL) assay; and apoptosis-related protein was detected by immunocytochemistry and Western blotting. RESULTS:Troglitazone inhibited growth and induced apoptosis of HepG2 cells in a dose-dependent manner, and induced activation of caspase-3 expression. Troglitazone not only drove apoptosis-inhibiting factor survivin to translocate incompletely from the nucleus to the cytoplasm, but also inhibited expression of survivin, while it did not affect expression of apoptosis-promoting factor Bax. CONCLUSION:PPAR gamma ligands inhibit growth and induce apoptosis of liver cancer cells, and may have applications for the prevention and treatment of liver cancer.
Authors: S Shin; B J Sung; Y S Cho; H J Kim; N C Ha; J I Hwang; C W Chung; Y K Jung; B H Oh Journal: Biochemistry Date: 2001-01-30 Impact factor: 3.162
Authors: L Fajas; D Auboeuf; E Raspé; K Schoonjans; A M Lefebvre; R Saladin; J Najib; M Laville; J C Fruchart; S Deeb; A Vidal-Puig; J Flier; M R Briggs; B Staels; H Vidal; J Auwerx Journal: J Biol Chem Date: 1997-07-25 Impact factor: 5.157
Authors: J Yamamoto; T Kosuge; T Takayama; K Shimada; S Yamasaki; H Ozaki; N Yamaguchi; M Makuuchi Journal: Br J Surg Date: 1996-09 Impact factor: 6.939
Authors: D J Mangelsdorf; C Thummel; M Beato; P Herrlich; G Schütz; K Umesono; B Blumberg; P Kastner; M Mark; P Chambon; R M Evans Journal: Cell Date: 1995-12-15 Impact factor: 41.582
Authors: H Sato; S Ishihara; K Kawashima; N Moriyama; H Suetsugu; H Kazumori; T Okuyama; M A Rumi; R Fukuda; N Nagasue; Y Kinoshita Journal: Br J Cancer Date: 2000-11 Impact factor: 7.640
Authors: V Mazzaferro; E Regalia; R Doci; S Andreola; A Pulvirenti; F Bozzetti; F Montalto; M Ammatuna; A Morabito; L Gennari Journal: N Engl J Med Date: 1996-03-14 Impact factor: 176.079
Authors: P J Simpson-Haidaris; S J Pollock; S Ramon; N Guo; C F Woeller; S E Feldon; R P Phipps Journal: PPAR Res Date: 2010-02-28 Impact factor: 4.964